Esophagitis is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Esophagitis have a 91.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Esophagitis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Esophagitis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Esophagitis overview

Esophagitis is inflammation of the esophagus, often triggered by acid reflux, infections, medications, or allergies. Symptoms include painful swallowing, heartburn, chest pain, and sometimes bleeding. Common types include reflux esophagitis (due to GERD) and infectious esophagitis (caused by viruses, fungi, or bacteria). Diagnosis involves endoscopy and sometimes imaging tests. Treatment focuses on addressing the underlying cause, using acid-suppressing medications, antibiotics, antifungals, or lifestyle changes. Complications can lead to strictures or Barrett’s esophagus, increasing the risk of esophageal cancer. Prompt diagnosis, targeted treatment, and managing underlying conditions are essential to alleviate symptoms and prevent complications in esophagitis.

For a complete picture of PTSR and LoA scores for drugs in Esophagitis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.